首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Mosapride combined with probiotics on gastrointestinal function and growth in premature infants
【2h】

Mosapride combined with probiotics on gastrointestinal function and growth in premature infants

机译:莫沙必利与益生菌联合对早产儿胃肠功能和生长的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to investigate the effects of mosapride combined with probiotics on gastrointestinal function and growth and development in premature infants. A total of 240 premature infants treated at Weifang People's Hospital between June 2012 and May 2015 who matched our criteria were randomly divided into three groups of 80 cases each. Group A received routine treatment, group B received routine treatment combined with live B. subtilis and E. faecium granules with multivitamins (Medilac-Vita), and group C received routine treatment and Saccharomyces boulardii sachets (Bioflor). Mosapride was administered to patients in groups B and C to promote intestinal peristalsis. Gastrin and bilirubin levels, as well as jaundice fade time, were recorded. Growth and development condition (i.e., head circumference and weight), duration and incidence of feeding intolerance (FI), as well as other symptoms were also analyzed. By day 14, gastrin concentrations in groups B and C were significantly higher than those in group A (P<0.05). Serum bilirubin levels in groups B and C showed a progressive decline from day 7 to day 14, and jaundice duration in group A was significantly longer (P<0.05). Furthermore, at 2 weeks, the average weight growth rate and head circumference were significantly greater in groups B and C, weight loss recovery time was shorter, and EUGR incidence was lower (P<0.05). The incidence rate of gastric retention and FI were lower in groups B and C than group A (P<0.05), and neonatal hyperbilirubinemia, parenteral nutrition-associated cholestasis, necrotizing enterocolitis, and neonatal sepsis incidence was significantly lower in groups B and C (P<0.05). Mosapride combined with probiotics can effectively reduce FI incidence in premature infants, shorten enteral feeding time, promote the absorption of required nutrients, and promote the development and recovery of early physiological weight loss in preterm infants.
机译:这项研究的目的是调查莫沙必利与益生菌联合对早产儿胃肠功能以及生长发育的影响。将2012年6月至2015年5月在潍坊市人民医院接受治疗的符合我们标准的240例早产儿随机分为三组,每组80例。 A组接受常规治疗,B组接受常规治疗,与活的枯草芽孢杆菌和屎肠球菌颗粒混合使用多种维生素(Medilac-Vita),C组接受常规治疗,而Saccharomyces boulardii香囊(Bioflor)。 B组和C组的患者服用莫沙必利以促进肠蠕动。记录胃泌素和胆红素水平以及黄疸消退时间。还分析了生长和发育状况(即头围和体重),持续时间和进食不耐症(FI)的发生率以及其他症状。到第14天,B和C组的胃泌素浓度明显高于A组(P <0.05)。 B和C组的血清胆红素水平从第7天到第14天呈逐渐下降的趋势,而A组的黄疸持续时间则明显更长(P <0.05)。此外,在2周时,B组和C组的平均体重增长和头围明显增加,体重减轻的恢复时间较短,EUGR发生率较低(P <0.05)。 B和C组的胃retention留和FI发生率低于A组(P <0.05),而B和C组的新生儿高胆红素血症,肠外营养相关胆汁淤积,坏死性小肠结肠炎和新生儿败血症发生率显着较低( P <0.05)。莫沙必利与益生菌的结合可有效降低早产儿的FI发生率,缩短肠内喂养时间,促进所需营养的吸收,并促进早产儿早期生理减肥的发展和恢复。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号